Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 5Head & Neck 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 8Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 14Gemcitabine 8Docetaxel 7Nivolumab 6durvalumab 5Cyclophosphamide 5130-nm albumin-bound paclitaxel 5atezolizumab 4Magnetic Resonance Spectroscopy 4Irinotecan 4sargramostim 3aldesleukin 3Specimen Handling 3Radiotherapy 3Paclitaxel 3Ipilimumab 3Fulvestrant 3Cisplatin 3Carboplatin 3venetoclax 2temsirolimus 2talazoparib 2spartalizumab 2olaparib 2liposomal doxorubicin 2fludarabine phosphate 2cabozantinib 2budigalimab 2avelumab 2Vinorelbine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × MLN 8237 × Breast × Clear all
NCT01045421 2016-08-15

Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies

Millennium Pharmaceuticals, Inc.

Phase 1/2 Completed
273 enrolled 28 charts
BreastHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡